insulin glargine (U100)

DRUG3 trials

Sponsors

Sanofi, Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2Type 2 DiabetesType 2 Diabetes Treated With Insulin

Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

CompletedNCT05462756

Eli Lilly and CompanyType 2 Diabetes, Type 2 Diabetes Treated With Insulin

Start: 2022-08-11End: 2024-02-27Updated: 2025-04-27

Phase 4

A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulins in Insulin Naïve Patients Initiating Insulin

CompletedNCT02967224

SanofiDiabetes Mellitus, Type 2

Start: 2015-11-05End: 2017-10-16Updated: 2022-04-25

A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulin in Patients Already Using Basal Insulin

CompletedNCT02967211

SanofiDiabetes Mellitus, Type 2

Start: 2015-12-21End: 2017-10-20Updated: 2022-04-25

Related Papers

Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program.

2026-01-27

Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.

2025-06-228 citations

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Current Medical Research and Opinion2019-12-2119 citations